Ultralife Corporation (ULBI) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals. Financial performance shows slight revenue growth and improved gross margins, but net income and EPS have declined YoY. While debt reduction is significant, the unclear management responses, particularly on Thin Cell opportunities, and concerns about supply chain dependencies and cyclical declines in oil and gas, create uncertainties. Despite strategic investments and a strong backlog, the lack of clarity and reliance on external factors balance out the positives, leading to a neutral sentiment.
Key Financial Performance
Consolidated Revenues $43 million, an increase of 0.7% from $42.7 million in Q2 2023, driven by strong performance in government defense and medical markets.
Battery & Energy Products Revenues $36.7 million, an increase of 8.3% from $33.9 million in Q2 2023, attributed to a 30.5% increase in government defense sales and a 20.1% increase in medical market sales.
Communications Systems Revenues $6.3 million, a decline of 28.7% from $8.8 million in Q2 2023, primarily due to delayed shipments of vehicle amplifier adapter orders.
Consolidated Gross Profit $11.6 million, up 9.2% from the previous year, reflecting a stronger gross margin of 26.9%, which improved by 210 basis points from 24.8% in Q2 2023.
Battery & Energy Products Gross Profit $10 million, an increase of 32% from $7.5 million in Q2 2023, with gross margin improving to 27.1%, up 480 basis points from 22.3%.
Communications Systems Gross Profit $1.6 million, down from $3 million in Q2 2023, with gross margin at 25.6%, down from 34.5%, primarily due to sales product mix and factory volume.
Operating Expenses $7.6 million, an increase of 10.4% from the previous year, attributed to investments in new product development and additional sales resources.
Operating Margin 9.1%, an increase from 8.6% in Q2 2023, due to improved gross margin.
Net Income $3 million, or $0.18 per share, compared to $3.3 million, or $0.21 per share in Q2 2023, impacted by the previous year's recognition of an employee retention credit.
Adjusted Fully-Diluted EPS $0.22 per share, down from $0.29 per share in Q2 2023, which included $0.10 per share from the employee retention credit.
Adjusted EBITDA $5.4 million, or 12.6% of sales, compared to $6.3 million, or 14.7% in the prior-year quarter, which included $1.5 million from the employee retention credit.
Working Capital $63.2 million, down from $66.5 million at the end of 2023.
Debt Reduction $13.2 million, or 52.2%, from $25.3 million to $12.1 million, significantly reducing interest expense.
Total Backlog $93 million, representing 55% of TTM sales.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Products: Several new next-generation amplification products are underway and nearing completion, including a radio-agnostic amplification product expected to be available for production orders by the end of the year.
Battery & Energy Products: Production equipment is in place for Thin Cell to support customers in the medical wearable space, with strong sales funnel growth in medical applications.
123A Product Line: Opportunity funnel growth in medical battery pack assemblies, with ongoing improvements to reduce costs and increase performance.
Thionyl Chloride Product Line: Continues qualification and field testing with several customers, currently in commercial discussions.
Market Expansion: Received a follow-on $5.5 million IDIQ from the U.S. government for radio power supplies and a $3.1 million logistics support contract.
International Orders: Received a $270,000 order from an international customer for the conformal wearable battery.
Operational Efficiencies: Paid down acquisition debt by over 52%, significantly decreasing interest expense and allowing for future M&A.
Gross Margin Improvement: Consolidated gross margin improved to 26.9%, driven by higher cost absorption and efficiencies.
Lean Productivity Initiatives: Hired a lean process veteran to improve manufacturing and back-office efficiencies, targeting a 3%-5% reduction in labor on high-volume lines.
Strategic Shifts: Focus on material cost deflation, lean productivity, and sales funnel improvement as top initiatives for 2024.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Economic Conditions: Uncertain global economic conditions could impact the company's performance.
Customer Revenue Dependence: Reductions in revenues from key customers pose a risk to financial stability.
Military Spending: Delays or reductions in U.S. and foreign military spending could adversely affect sales.
Product Acceptance: Acceptance of new products on a global basis remains uncertain.
Supply Chain Disruptions: Disruptions or delays in the supply of raw materials and components due to various factors could hinder operations.
Global Conflicts and Weather: Global conflicts and weather-related issues may disrupt business operations.
Regulatory Issues: Potential regulatory challenges could impact business activities.
Cybersecurity Risks: Ongoing issues related to a previous cyberattack may affect financial results.
Debt Management: While debt reduction is a priority, managing it alongside business investments poses a challenge.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Top 3 Initiatives for 2024: 1. Material cost deflation: Favorable negotiations on logistics contracts expected to yield savings. 2. Lean productivity: Hiring a lean process veteran to improve efficiencies, targeting a 3-5% reduction in labor on high-volume lines. 3. Sales funnel improvement: Hiring additional sales resources to enhance commercial sales growth and transitioning to a new global CRM system.
Debt Reduction: Paid down acquisition debt by over 52%, significantly decreasing interest expense and allowing for future accretive M&A.
New Product Development: Advancements in next-generation amplification products and Thin Cell production for medical applications, with strong sales funnel growth.
Revenue Expectations: Expect incremental orders in 2024, with a strong sales funnel across new and existing products.
Gross Margin Improvement: Expect steady improvement in gross margins as CapEx investments and lean projects are implemented.
Debt Paydown Strategy: Strategically pay down debt throughout 2024 while balancing investments to support key objectives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Debt Paydown: Ultralife Corporation reduced its debt by $13.2 million, or 52.2%, from $25.3 million to $12.1 million during Q2 2024.
Interest Expense Reduction: The $13 million paydown of debt is expected to lower interest expense by approximately $234,000 in the third quarter.
Impact on EPS: The debt reduction equates to $0.01 of GAAP EPS and $0.015 of adjusted EPS.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think of free cash generation going forward? Can we stay at these levels? What are the priorities for cash?
A:The level-loading has been a major help for us, improving the supply chain and cash flow. We expect to continue reducing debt while balancing it with strategic spending opportunities.
Q:What inning do you think we're in regarding your strategic plan?
A:We're early in the game, having tackled the easier issues first. The efficiency journey is ongoing and will continue to evolve.
Q:Do you feel the growth in the battery segment can continue with the 2025 defense budget?
A:There are no significant decreases expected in the programs we are involved with, but we are dependent on our customers' supply chain issues.
Q:Is there anything going on cyclically in the decline in oil and gas?
A:It seems to be related to overbuying by a couple of customers and some reorganization on their part. We expect volume to rebound in the latter half of the year.
Q:Could the Thin Cell opportunities be a major gating event? How quickly can you ramp up to support that product?
A:We hope it will be a major event, but we haven't landed an anchor customer yet. It takes time, as seen with previous medical customers.
Q:Where are the new sales resource investments going?
A:One resource is focused on moving Thin Cell and Thionyl into bigger accounts, while another is developing relationships with major medical device manufacturers.
Q:Why are you continuing to invest in the IVAS battery? What other programs could use that technology?
A:We aim to develop technology that is agnostic and versatile. The need for power in military applications is increasing, and we want to be a complete soldier power supplier.
Q:Review of Unclear Management Responses
A:Management's response regarding the Thin Cell opportunities lacked clarity, particularly in terms of timelines and the specifics of customer engagement.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CRM system
Cell
ERC
Land Warrior
OEM
Thionyl
Warrior battery
amplification product
business
carrier
conformal product
contract
conversation
debt paydown
decade
device manufacturer
focus
game
generation
industry veteran
investment product
level loading
location
lot
manufacturing
office
opportunity funnel
people
platform
relationship
sale funnel
sale resource
shipment period
soldier
stage
status
supplier
ULBI Transcript
Ultralife Corporation (ULBI) Q3 2025 Earnings Call Transcript
Unknown11-18
The earnings call presented mixed signals: strong revenue growth and new product development were offset by declining margins, increased operating expenses, and net losses. The absence of Q&A questions suggests no immediate analyst concerns, but macroeconomic factors and supply chain issues pose risks. With no clear catalyst for a strong move, the stock is likely to remain neutral in the short term.
Ultralife Corporation (ULBI) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call reveals several concerning aspects: a decline in operating income and net profit, decreased communication systems revenue, and increased operating expenses. The Q&A section highlights risks such as tariffs, cyber attack impacts, and lack of specific guidance on potential opportunities. While there is optimism about future growth, the lack of concrete figures and ongoing challenges contribute to a negative sentiment, likely resulting in a stock price decline.
Ultralife Corporation (NASDAQ:ULBI) Q1 2025 Earnings Call Transcript
Unknown5-11
The earnings call reveals mixed signals. While revenue grew 21% YoY, operating income and EPS decreased due to increased expenses and acquisition costs. Strong government-defense sales were offset by declines in other segments. The Q&A highlighted concerns over tariffs and vague management responses, but also noted confidence in transformational projects and steady medical markets. Despite no share repurchase program, the backlog and working capital indicate demand and liquidity. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement in either direction.
Ultralife Corporation (ULBI) Q1 2025 Earnings Call Transcript
Unknown5-9
Despite a strong revenue increase and optimistic guidance, the lack of a share repurchase program and concerns about tariffs, military spending, and product acceptance pose risks. The Q&A highlights potential operational challenges and unclear management responses. These factors, combined with decreased net income and operating income, suggest a mixed outlook, leading to a neutral rating. Without a market cap, the stock's reaction remains uncertain, but the absence of a share repurchase plan and potential operational issues are likely to temper any positive financial news.
ULBI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
